Prognostic significance of BCR-ABL rearrangement in childhood acute lymphoblastic leukemia
DOI:
https://doi.org/10.12775/MBS.2014.034Keywords
acute lymphoblastic leukemia, children, prognostic factorsAbstract
B a c k g r o u n d . Acute lymphoblastic leukemia (ALL) is the most frequent pediatric malignancy. Presence of adverse risk factors determines risk group stratification in this disease.
O b j e c t i v e . The aim of study was the analysis of results of therapy and role of prognostic risk factors in treatment of childhood ALL in kujawsko-pomorskie region in 1995-2010.
P a t i e n t s a n d m e t h o d s . During this period, ALL was diagnosed in 223 patients. With respect to time period and therapy protocol, the patients were divided into two groups: group 1 A/B (1995-2002) and group 2 (2002- 2010). Probability of overall survival (OS), event-free survival (EFS) and relapse-free survival (RFS) were analyzed. Uni- and multivariate analyzes for risk factors were performed.
R e s u l t s . Over the analyzed 17-year period, OS has increased from 77.9% in group 1A and 73.7% in group 1B to 86.2% in group 2. Results of RFS and EFS have also increased during this time. The death rate has decreased from 26% in group 1A and 26.3% in group 1B to 10.2% in group 2. The most important adverse prognostic risk factors during the first period included involvement of liver, spleen, lymph nodes as well as poor response to initial therapy, while during the second period the most important independent risk factor was BCR-ABL rearrangement in lymphoblasts.
C o n c l u s i o n s . The most important independent prognostic risk factors in pediatric ALL include advanced disease, BCR-ABL rearrangement, and initial response to therapy. These factors are used for stratification to treatment groups, intensification of therapy and hematopoietic stem cell transplantation.
References
Pui CH, Relling MV, Downing JR: Acute lymphoblastic leukemia. N Engl J Med 2004;350:1535-1548.
Arico M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A, Gaynon P, Silverman L, Janka- Schaub G, Kamps W, Pui CH, Masera G: Outcome of treatment in children with Philadelphia chromosomepositive acute lymphoblastic leukemia. N Engl J Med 2000;342:998-1006.
Stock W, Estrov Z: Studies of minimal residual disease in acute lymphocytic leukemia. Hematol Oncol Clin North Am 2000;14:1289-1305.
Jeha S, Coustan-Smith E, Pei D, Sandlund JT, Rubnitz JE, Howard SC, Inaba H, Bhojwani D, Metzger ML, Cheng C, Choi JK, Jacobsen J, Shurtleff SA, Raimondi S, Ribeiro RC, Pui CH, Campana D: Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 2014;120:1514- 1519.
Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W, Niemeyer C, Henze G, Feldges A, Zintl F, Kornhuber B, Ritter J, Welte K, Gadner H, Riehm H: Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM study group. Blood 2000;95:3310-3322.
Kwiecinska K, Balwierz W, Moryl-Bujakowska A, Wachowiak J, Derwich K, Matysiak M, Pawelec K, Chybicka A, Dobaczewski G, Kowalczyk JR, Wisniewska-Slusarz H, Sonta-Jakimczyk D, Szczepanski T, Tomaszewska R, Wysocki M, Styczynski J, Balcerska A, Ploszynska A: Long-term observations of children with acute lymphoblastic leukemia and high leukocytosis treated according to modified "New York" protocols (1987-2003). Przegl Lek 2010;67:350-354.
Steinherz PG, Redner A, Steinherz L, Meyers P, Tan C, Heller G: Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol. Cancer 1993;72:3120-3130.
Stary J, Zimmermann M, Campbell M, Castillo L, Dibar E, Donska S, Gonzalez A, Izraeli S, Janic D, Jazbec J, Konja J, Kaiserova E, Kowalczyk J, Kovacs G, Li CK, Magyarosy E, Popa A, Stark B, Jabali Y, Trka J, Hrusak O, Riehm H, Masera G, Schrappe M: Intensive chemotherapy for childhood acute lymphoblastic leukemia: Results of the randomized intercontinental trial ALL IC-BFM 2002. J Clin Oncol 2014;32:174-184.
van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, Gottardi E, Rambaldi A, Dotti G, Griesinger F, Parreira A, Gameiro P, Diaz MG, Malec M, Langerak AW, San Miguel JF, Biondi A: Standardized rt-pcr analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 concerted action: Investigation of minimal residual disease in acute leukemia. Leukemia 1999;13:1901-1928.
Moricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H, Ludwig WD, Ritter J, Harbott J, Mann G, Klingebiel T, Zintl F, Niemeyer C, Kremens B, Niggli F, Niethammer D, Welte K, Stanulla M, Odenwald E, Riehm H, Schrappe M: Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010;24:265- 284.
Arico M, Schrappe M, Hunger SP, Carroll WL, Conter V, Galimberti S, Manabe A, Saha V, Baruchel A, Vettenranta K, Horibe K, Benoit Y, Pieters R, Escherich G, Silverman LB, Pui CH, Valsecchi MG: Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol 2010;28:4755-4761.
Hunger SP, Baruchel A, Biondi A, Evans WE, Jeha S, Loh M, Moericke A, Pieters R, Relling MV, Schmiegelow K, Schrappe M, Silverman LB, Stanulla M, Valsecchi MG, Vora A, Pui CH: The thirteenth international childhood acute lymphoblastic leukemia workshop report: La Jolla, CA, USA, December 7-9, 2011. Pediatr Blood Cancer 2013;60:344-348.
Schrappe M, Hunger SP, Pui CH, Saha V, Gaynon PS, Baruchel A, Conter V, Otten J, Ohara A, Versluys AB, Escherich G, Heyman M, Silverman LB, Horibe K, Mann G, Camitta BM, Harbott J, Riehm H, Richards S, Devidas M, Zimmermann M: Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med 2012;366:1371-1381.
Buitenkamp TD, Izraeli S, Zimmermann M, Forestier E, Heerema NA, van den Heuvel-Eibrink MM, Pieters R, Korbijn CM, Silverman LB, Schmiegelow K, Liang DC, Horibe K, Arico M, Biondi A, Basso G, Rabin KR, Schrappe M, Cario G, Mann G, Morak M, Panzer- Grumayer R, Mondelaers V, Lammens T, Cave H, Stark B, Ganmore I, Moorman AV, Vora A, Hunger SP, Pui CH, Mullighan CG, Manabe A, Escherich G, Kowalczyk JR, Whitlock JA, Zwaan CM: Acute lymphoblastic leukemia in children with Down syndrome: A retrospective analysis from the Ponte di Legno Study Group. Blood 2014;123:70-77.
Dębski R, Sędek Ł, Jaworska-Posadzy A, Sonsala A, Kołtan A, Szczepański T, Pogorzała M, Wysocki M, Styczyński J: Monitorowanie i walidacja minimalnej choroby resztkowej metodą cytometrii przepływowej w ostrej białaczce limfoblastycznej u dzieci Post Nauk Med 2014:225-230
Styczynski J, Piatkowska M, Jaworska-Posadzy A, Czyzewski K, Kubicka M, Kolodziej B, Kurylo-Rafinska B, Debski R, Pogorzala M, Wysocki M: Comparison of prognostic value of in vitro drug resistance and bone marrow residual disease on day 15 of therapy in childhood acute lymphoblastic leukemia. Anticancer Res 2012;32:5495-5499.
Downloads
Published
How to Cite
Issue
Section
Stats
Number of views and downloads: 301
Number of citations: 0